Therapeutic strategies targeting CD47-SIRPα signaling pathway in gastrointestinal cancers treatment.
10.1016/j.jpha.2024.101099
- Author:
Zhengping CHE
1
;
Wei WANG
2
;
Lin ZHANG
3
;
Zhenghong LIN
1
Author Information
1. School of Life Sciences, Chongqing University, Chongqing, 401331, China.
2. Department of Cancer Center, Chongqing University Three Gorges Hospital, School of Medicine, Chongqing University, Chongqing, 404000, China.
3. Department of Gastroenterology, Chongqing University Jiangjin Hospital, Chongqing, 402260, China.
- Publication Type:Review
- Keywords:
CD47-SIRPα;
GI cancers;
Immune checkpoint blockade;
Immunotherapy;
Signaling pathway
- From:
Journal of Pharmaceutical Analysis
2025;15(1):101099-101099
- CountryChina
- Language:English
-
Abstract:
Gastrointestinal (GI) cancers are prevalent globally, with leading incidence and mortality rates among malignant tumors. Despite notable advancements in surgical resection, radiotherapy, and chemotherapy, the overall survival rates remain low. Hence, it is imperative to explore alternative approaches that enhance patient outcomes. Cluster of differentiation 47 (CD47), serving as an early diagnostic marker, is predominantly overexpressed in GI cancers and associated with poor prognosis. Targeting the CD47-signal regulatory protein alpha (SIRPα) signaling pathway may provide a novel strategy for GI cancers treatment. This study summarizes current knowledge of the structure and function of CD47 and SIRPα, their roles in signaling pathways, the prognostic significance of CD47, therapeutic strategies targeting the CD47-SIRPα signaling pathway in GI cancer, and highlights key issues for future investigations.
